Kelly D Getz
University of Pennsylvania · Rehabilitation Medicine
Active 1985–2026
Academic metrics are sourced from OpenAlex and public funding records; values may differ from Google Scholar.
About
Kelly D Getz, PhD, MPH, is an Assistant Professor of Epidemiology in Biostatistics and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania. He is an investigator at the Center for Real-world Evidence on the Effectiveness and Safety of Therapeutics (CREST) and a Senior Scholar at the Center for Clinical Epidemiology & Biostatistics. His research interests broadly focus on the treatment and supportive care of children and young adults with cancer, with an emphasis on understanding and balancing therapeutic benefits and toxicity risks. He has a specific interest in the emerging field of cardio-oncology, particularly in the early detection of cardiotoxic side effects of cancer treatments and in mitigating cardiac disease as a barrier to effective cancer therapy. Additionally, he is engaged in identifying and reducing disparities in the treatment and outcomes of pediatric cancers. Dr. Getz's educational background includes a BS in Biology from Millersville University, an MPH in Epidemiology from Boston University School of Public Health, and a PhD in Epidemiology from the same institution. His work contributes to advancing knowledge in pediatric oncology, cardio-oncology, and health disparities, with numerous publications in these areas.
Research topics
- Medicine
- Internal medicine
- Oncology
- Immunology
- Cardiology
Selected publications
Journal of Clinical Oncology · 2021 · 185 citations
PURPOSE: CD19-targeted chimeric antigen receptor (CAR)-modified T cells demonstrate unprecedented responses in B-cell acute lymphoblastic leukemia (B-ALL); however, relapse remains a substantial challenge. Short CAR T-cell persistence contributes to this risk; therefore, strategies to improve persistence are needed. METHODS: We conducted a pilot clinical trial of a humanized CD19 CAR T-cell product (huCART19) in children and young adults with relapsed or refractory B-ALL (n = 72) or B-lymphoblas…
Journal of the American Heart Association · 2020 · 160 citations
Background We examined the longitudinal associations between changes in cardiovascular biomarkers and cancer therapy-related cardiac dysfunction (CTRCD) in patients with breast cancer treated with cardotoxic cancer therapy. Methods and Results Repeated measures of high-sensitivity cardiac troponin T (hs-cTnT), NT-proBNP (N-terminal pro-B-type natriuretic peptide), myeloperoxidase, placental growth factor, and growth differentiation factor 15 were assessed longitudinally in a prospective cohort o…
Evolving racial/ethnic disparities in AML survival in the novel therapy era
Blood Advances · 2025-01-31 · 10 citations
articleOpen accessABSTRACT: Little is known about the impact of recent advances in acute myeloid leukemia (AML) treatment on racial/ethnic disparities in survival outcomes. We performed a retrospective cohort study of patients with newly diagnosed AML using data from a nationwide electronic health record-derived deidentified database. Patients were categorized based on their diagnosis date relative to venetoclax approval, as pre-novel therapy era (Pre era; 2014-2018; n = 2998) or post-novel therapy era (Post era;…
Blood Advances · 2024-11-20 · 6 citations
articleOpen accessCD19-targeted chimeric antigen receptor (CAR) T-cell therapy (CAR19) produces remarkably high remission rates in relapsed/refractory pediatric B-cell acute lymphoblastic leukemia (B-ALL); however, approximately 50% of children and young adults experience another relapse within 2 years after infusion. [1][2]2][3][4] Although the majority of post-CAR19 relapses are isolated to the bone marrow (BM), extramedullary disease (EMD) is not uncommon.Up to 34% of post-CAR19 relapses include EMD, either in…
JNCI Journal of the National Cancer Institute · 2026-01-28
articleOpen accessMore than 60% of adult survivors of childhood cancer report medical financial hardship due to the cumulative costs of cancer-directed therapy and related chronic health conditions. Whether neurocognitive impairment as a late effect is associated with increased financial hardship is unknown. In a large national cohort of 3023 adult survivors of childhood cancer, we observed a dose-dependent relationship between neurocognitive impairment and financial hardship outcomes. Individuals with 4 impaired…
Recent grants
NIH · $2.3M · 2022–2027
NIH · $716k · 2018–2024
Frequent coauthors
- 208 shared
Richard Aplenc
Hospital for Sick Children
- 152 shared
Yimei Li
Children's Hospital of Philadelphia
- 132 shared
Brian T. Fisher
University of Pennsylvania
- 96 shared
Tamara P. Miller
Children's Healthcare of Atlanta
- 93 shared
Alix E. Seif
Children's Hospital of Philadelphia
- 69 shared
M. Monica Gramatges
Texas Children's Hospital
- 52 shared
Todd A. Alonzo
Children's Oncology Group
- 50 shared
Yuan‐Shung Huang
Children's Hospital of Philadelphia
Similar researchers at University of Pennsylvania
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Kelly D Getz
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup